Voice recordings to watch for nerve-related side effects of CAR T-cell therapy
Looks at voice recordings to monitor side effects in adults receiving CAR T-cell therapy.
Plain-language title generated from the registry record
Registry title: A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Key facts
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 8 sites
Where in United States
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesTaking people
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesTaking people
- Memorial Sloan Kettering Westchester (Consent only)Harrison, United StatesTaking people
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, United StatesTaking people
- Memorial Sloan Kettering Bergen (Consent Only)Montvale, United StatesTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)New York, United StatesTaking people
- Weill Cornell Medical Center (Data Analysis Only)New York, United StatesNot yet recruiting
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT07249528
- Record updated
- 13 October 2026
- Original description
The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell therapy. Researchers will study whether these voice recordings and assessments are a practical (feasible) way to monitor for immune effector cell-associated neurotoxicity syndrome (ICANS). Feasibility will be measured by tracking how many participants join the study and complete the assessments.Read full original descriptionShow less
Voice as a Digital Biomarker of Neurotoxicity in CAR T-Cell Therapy
The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell therapy. Researchers will study whether these voice recordings and assessments are a practical (feasible) way to monitor for immune effector cell-associated neurotoxicity syndrome (ICANS). Feasibility will be measured by tracking how many participants join the study and complete the assessments.
Inclusion: Documentation of Disease; o Patients must have pathologically confirmed Diagnosed with non-Hodgkin lymphoma or multiple myeloma; Definition of treatment and ability; Scheduled to receive an FDA-approved CAR-T product: Axi-cel, Liso-cel, Tisa-cel, Ide-cel, Cilta-cel, or Brexu-cel; Ability to comply with twice daily voice recordings or daily neurologic assessments, as determined by the investigator; Age ≥ 18; ECOG Performance Status of ≤ 2; Required; Perform twice daily voice recordings using a smartphone; Undergo daily neurologic assessments (e.g., ICE score, tremor evaluation); Smartphone ownership; Sufficient English proficiency to complete structured voice tasks in the study application; Comorbid Conditions; No pre-existing neurological conditions that significantly impair speech, including but not limited to severe dysarthria, expressive aphasia, or neurodegenerative disorders; No history of significant speech or voice disorders, including laryngeal paralysis, severe dysphonia, or recent vocal cord surgery or radiation to the area; No pathology affecting the vocal cords that could interfere with voice analysis, such as vocal cord paralysis, chronic laryngitis, vocal cord nodules, polyps, granulomas, or malignancies; No severe hearing impairment that would interfere with voice assessments; Language o Proficiency in spoken English is required, without the need for native-level fluency. This ensures participants can accurately perform structured voice tasks, as the application and underlying acoustic models are currently validated only in English, despite the limitation in generalizability. Participants with language barriers that prevent reliabletask completion or data interpretation will be excluded.